believeyear review year review contents believe believe believe believe believe anything discovery one business possible never ends people alone sustainable purpose science innovation working gilead community impact practices environment appendix report science driving people make difference providing access smarter smaller footprint gilead medicines message chairman groundbreaking research welcome celebrate sustainability climate governance ceo daniel o'day development diverse perspectives giving back change environment communities global health gri content index looking partnerships global workforce behind work year review year review report standardize data collection measurement reporting activities use industryleading frameworks united nations global compact ungc united nations sustainable development goals un sdgs global reporting initiative gri carbon disclosure project cdp frameworks gileads year review organized accordance core reporting framework defined gri standards report covers topics listed gri content index entities listed companys sec filings httpinvestorsgileadcomfinancialinformationsecfilings website report content period boundary following gris principles defining report content gilead considered stakeholder inclusiveness sustainability context materiality completeness reporting principles refer gri content index additional information reporting period boundaries indicator included report differ metrics based data availability publication date report indicators reporting periods provide updated data regularly reevaluate reporting boundaries material topics ensure current complete year review year review welcoming daniel oday chairman chief executive officer daniel oday named chairman ceo following departure former president ceo john f milligan phd end dan appointed following comprehensive search led board directors selected based record success highly scientific competitive therapeutic areas deep understanding evolving global healthcare environment unwavering commitment driving innovation serve gilead continuing quest transform patients lives around world year review year review message daniel o'day chairman ceo believe people throughout career ive privilege working many smart join colleagues remarkable company im humbled passionate individuals ive seen firsthand people achieve theyre opportunity excited potential see time given inclusive work environment every person every voice receives unprecedented change industry companies possess resources equal value important ensure people always given employee passion longstanding commitment science innovation opportunities learn grow achieve greatest potential grateful gilead shown years part company puts emphasis diversity inclusion core value essential gileads longterm success new challenges greater potential progress ever gilead wellpositioned build legacy delivering transformational medicines believe business sustainable patients dedicated discovering developing lifesaving medicines large global company understand impact daytoday operations also recognize science alone cant solve worlds toughest healthcare people environment help ensure continue execute challenges believe putting patients first numerous ways mission providing lifesaving medicines areas unmet need built supporting access healthcare services around world forging corporate social responsibility csr program supports patients society partnerships patient advocacy groups healthcare professionals planet business gilead established csr committee help ensure business meets highest social environmental standards ive spent lot time thinking gileads unique role leader ability approach csr continued support ungcun sdgs reaffirms shape future healthcare era change seek discover commitment drive short medium longterm action areas human develop commercialize innovative therapeutics areas unmet medical rights labor environment anticorruption needs role defined three core beliefs chairman ceo committed ensuring gilead makes believe discovery never ends unprecedented time industry excited gilead work behind every medication gilead developed last three decades alongside talented employees harness collective commitment group dedicated individuals across entire company united common right patients desire make groundbreaking discoveries help patients save lives sense purpose allowed gilead make difference world thank believing us shared commitment made possible prevention treatment hiv aids fueled quest may one day lead finding cure hiv daniel oday driven us pursue cure cancer work field cell therapy led development cure hepatitis c year review year review looking total revenue gilead strive transform promise science technology b therapies power cure prevent treat diseases revolutionize standard care believe approach innovation relentlessly pursuing best breakthroughs science whether come within labs partnerships industry leaders looking back year strong consistent operational financial execution across portfolio hiv hcv cardiovascular oncology also made great progress strengthening pipeline product sales largely driven successful launch biktarvy continued uptake descovy genvoya odefsey total revenue hiv medicines increased billion billion previous year even overall product sales decreased com pared notably due unique dynamics curative nature hepatitis c virus hcv products oncology sales grew substantially total million b cash b cash dividends paid sales yescarta chimeric antigen receptor car cell therapy operations stockholders collaborations b c eqa ush iv c lea ns th b share marketable securities repurchases gilead entered partnerships licensing merger acquisition equity investment deals significantly enhance research pipeline therapeutic areas including hiv inflammation immunotherapy oncology liver disease b research b development debt include collaborations pfizer sangamo therapeutics verily national expenses repaid cancer institute hookipa gadeta trianni precision biosciences hifibio therapeu tics tango therapeutics scholar rock agenus purpose purpose believe anything possible foeuatru pruer sptoosrey purpose never really expected people like would living hiv long hear douglas ' story words learn gilead 's work treat prevent ultimately end believe nearly years diagnosed hiv douglas brooks anything alive healthy words thanks gilead hiv epidemic visit possible patientturnedemployee doug living proof inspiration gileadcomyir discover develop breakthrough hiv treatments purpose behind work mission gileads mission discover believe relentlessly pursuing breakthroughs science whether develop commercialize innovative come within labs partnerships therapeutics areas unmet primary purpose help people lifethreatening diseases work built medical needs four pillars enable us develop deliver innovative medicines upporting patients patientsfirst approach demonstrated collaboration patient advocacy organizations work discover develop therapies core revolutionize standard care cure diseases offering comprehensive support programs help meet needs patients caregivers values science innovation research well partnerships universities medical research institutions global pharmaceutical leaders gilead bringing forward scientific clinical advancements prevent treat ntegrity cure lifethreatening diseases nclusion inclusiveness promote highperforming workplace culture informed diverse set believe backgrounds experiences points view enables employees embrace eamwork anything leverage others talents diverse perspectives foster sense belonging possible purpose achieve full career potential contribute gileads success ccountability giving back recognize patients communities often face challenges accessing best possible care know passion scientific discovery alone e xcellence gilead alone solve challenges partnerships community organizations approach corporate philanthropy support initiatives programs improve access care reduce disparities improve education support local communities purpose address global challenges united nations global compact ungc calls companies align operations universally accepted principles human rights labor environment anticorruption gilead became signatory member joining industryleading companies supporting united nations sustainable development goals un sdgs stemming ungc un sdgs identify impact areas improve quality life people aligning existing sustainability social practices within ungc un sdgs better articulate commitment patients local communities society planet although gilead supports sdgs identified key goals deliver greatest influence positive impact particular gileads mission provide lifesaving therapeutics marginalized underserved communities aligns strongly sdg good health wellbeing gilead expands business operations strive support global health sustainable development priority sdgs displayed pages sdg icons also used throughout report highlight areas work corresponds specific goals additional information alignment work sdgs found gri content index report purpose purpose good health wellbeing industry innovation infrastructure expand access innovative therapeutics improve human health leverage science innovation develop industryleading worldwide aim help end epidemics aids hepatitis therapeutics areas unmet medical need combat communicable diseases quality education reduced inequalities educate train healthcare providers advanced therapies especially formed diversity council enhance inclusion lowincome developing regions diversity initiatives worldwide gender equality responsible consumption production cultivate inclusive diverse workforce celebrates differences use green sustainable chemistry possible produce race age gender sexual orientation gender identity thinking style therapies benefit human health minimize environmental impact clean water sanitation climate action protect waterdependent ecosystems using natural bioswales committed reducing greenhouse gas emissions rainwater capture systems water conservation measures compared levels believe affordable clean energy partnerships goals anything possible generate purchase renewable energy offset gridsupplied forge internal external partnerships improve patient care strengthen health systems reduce social energy worldwide facilities environmental impacts science innovation science innovation believe discovery never ends sciefnecaet ur ein sntoovraytion science innovation treating cancer else fails denise diagnosed lymphoma birthday learn two different chemotherapy regimens failed treat 're working bring tumors told six months live hope patients like believe discovered car cell therapy enrolled patient denise visit discovery one cell therapy trials cuttingedge treatment would never gileadcomyir ends engineer immune system attack cancer science innovation science innovation science driving gilead science innovation goal develop lifesaving products make difference patients around world envision world disease treatable curable preventable years used scientific expertise develop therapies revolutionize standard care many diseases still recognize science alone enough also support innovative partnerships address challenges make certain communities disproportionally believe susceptible disease discovery never ends also invest communities apply rigor use scientific innovation support sustainable programs focus intersection diseases like hiv social determinants health portfolio marketed products target areas significant unmet medical need including hivaids liver diseases hematology oncology inflammatory diseases respiratory diseases science innovation science innovation groundbreaking research development expanding treatment include investigational longacting injectables could potentially gileads portfolio features number category firsts including complete treatment access china administered month even regimens hiv chronic hepatitis c virus hcv infection available oncedaily every three months longer one single pills yescarta first chimeric antigen receptor car cell therapy compounds gs investigational gileads presence china adult patients relapsed refractory large bcell lymphoma small molecule capsid inhibitor designed expanded significantly disrupt protein shell protects china national medicinal products today research development efforts include hundreds ongoing viral genome interfering two stages administration nmpa approving planned clinical studies evaluating compounds potential become viruss replication cycle gs epclusa genvoya vemlidy medicines set new standard care end research harvoni descovy clinical trials looking development pipeline included active clinical studies drugs pair create potentially phase clinical trials increasing access safe effective welltolerated longacting effective treatments vital public treatment regimen health worlds populous country addition developing new treatment new therapies hiv new hiv diagnoses options gilead committed prevention estimated million people living hiv infection appropriate individuals decades gilead leader developing innovative therapies help hcv use truvada prep pre treat hiv gileads newest hiv therapy biktarvy daily single tablet regimen exposure prophylaxis oncedaily tablet combining bictegravir emtricitabine tenofovir alafenamide taf approved gilead employees first medication approved help fda february biktarvy found effective tolerable work china prevent hiv infection prep one approach adults new treatment well stably suppressed adult patients transitioning helping individuals hivnegative believe medicines united states biktarvy prescribed product risk hiv infection reduce chances discovery first months compared products launched treat hiv never acquiring hiv sex gilead ends single tablet regimen help make simpler patients compared launched first us television advertisement earliest hiv treatments required dozens medications taken truvada prep help raise awareness day multiple times day still scientists continue work developing new encourage people higher treatments goal making even easier patients adhere providing risk hiv exposure candid additional treatment dosing schedule options well compounds conversation hiv prevention may effective patients whose disease showing greater resistance healthcare provider science innovation science innovation biktarvy united states biktarvy prescribed product first months compared products launched treat hiv worldwide sales b believe discovery never ends science innovation science innovation kite advancing state oncology gilead acquired kite pharma solidifying dedication helping achieve one ambitious goals st century medicine curing cancer continued advance pipeline cancer therapies including cell therapy immunotherapy targeted therapy kites cell therapy portfolio led yescarta axicabtagene ciloleucel first chimeric antigen receptor car cell therapy approved fda treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy yescarta works genetically modifying immune cells target tumors effectively reengineering patients cells detect kill cancer cells european commission granted marketing authorization yescarta august support patients europe kite established distribution center netherlands building manufacturing facility expected begin operating achievements kite capped one prestigious honors approach tackling liver diseases biopharmaceutical research yescarta named cowinner prix galien usa award best biotechnology product prix galien aims promote significant advances gilead developed breakthrough medicines cure patients hepatitis c pharmaceutical research year award gives credit important drugs virus hcv infection regardless virus genotype cirrhosis status gilead introduced public market well achievements best research developed vemlidy helps people living hepatitis b virus hbv infection team pharmaceutical field considered industrys equivalent nobel control condition every day small oncedaily tablet prize highest accolade pharmaceutical research development believe discovery know caring people living chronic illnesses never addition ongoing studies yescarta kite advancing novel investigational ends medicine screening increasing patient access treatment critical thats therapies range hematologic malignancies solid tumors continue work expand hepatitis screening linkage care also advancing oncology research partnerships licensing atrisk individuals increase access medicines around world agreements mas strategic investments founding member actively support efforts governments partner professional foundation national institute healths partnership accelerating cancer organizations patient advocacy groups payers healthcare professionals therapies gilead collaborates peers enhance understanding cancer declared intention commitment work toward world health immunotherapy engineered cell therapies organization goal elimination viral hepatitis around world science innovation science innovation epclusa first pangenotypic panfibrotic treatment accounts advancing potential treatments inflammatory diseases majority gileads hcv product sales united states hcv sales europe nmpa approved epclusa harvoni despite several available effective medications patients rheumatoid treatment hcv vemlidy treatment hbv bringing new treatment arthritis ra inflammatory bowel disease ibd inflammatory conditions options millions people china living viral hepatitis existing treatments stop providing adequate control symptoms time believe additional treatment options needed aim hbv continue work toward goal finding cure gilead shared break efficacy ceiling patients inflammatory conditions numerous research findings scientific community entered new strategic partnerships supplement inhouse research galapagos gilead entered global collaboration development commercialization filgotinib investigational jak inhibitor also developing medicines nonalcoholic steatohepatitis nash inflammatory indications may gilead galapagos announced primary sclerosing cholangitis psc nash disease causes fat accumulation equator phase trial filgotinib psoriatic arthritis met primary endpoint inflammation liver lead liver fibrosis expected become gilead galapagos announced phase b selection trial filgotinib leading cause liver transplantation psc rare chronic condition ulcerative colitis progressed phase following interim futility analysis damages bile ducts lead cirrhosis liver failure cancer data monitoring committee dmc recommended study proceed treatments cure psc stop disease progression planned evaluating mg mg oncedaily doses biologicexperienced biologicnave patients september gilead galapagos announced gilead advancing multiple novel investigational compounds treatment tortuga phase trial filgotinib ankylosing spondylitis met primary advanced fibrosis due nash currently conducting phase trial psc endpoint time gilead galapagos announced phase finch trial ra patients refractory biologics met primary key secondary endpoints line previous studies results equator believe asegua bridging gap treatment tortuga published lancet discovery never filgotinib lead asset therapeutic area potential establish ends asegua therapeutics gilead subsidiary produces authorized generics foundation gilead combination treatment strategies improve outcomes epclusa harvoni offering health insurers lower list price option patients ra ibd inflammatory diseases continue develop hcv medications pricing authorized generics closely reflects existing internal compounds actively evaluating external opportunities discounting branded products providing payers policy contractual complement accelerate internal efforts constraints option may enable easily provide coverage insured populations ultimately offer promise treatment cure patients throughout united states science innovation science innovation research structured research research collaboration acquisition collaboration collaboration immunophenotyping tcells buildto buy electroporation modulation latent platform inflam cell therapy tgffor fibrosis research research research outlicensing research research research research collaboration collaboration collaboration momelotinibfor collaboration collaboration collaboration collaboration gene editing cell therapies vaccines myeloproliferative gene editing neoantigen tcrs hiv cure bispecific abs io cell therapy targeting patient hivhbv cure diseases hbv cure specific tumor neoantigens believe clinical study clinical study product research research collaboration collaboration acquisition collaboration collaboration discovery yescarta gs hiv products crispr screening novel small never utomilumab vaccine japan io molecules ends lbcl hiv cure fibrosis dna gnisnecil spihsrentrap stnemtsevni ytiuqe partnerships collaborations include strategic collaboration precision biosciences develop therapies targeting vivo elimination hbv precisions proprietary genome editing platform arcus research collaboration license agreement grants gilead exclusive rights hookipas therat vaxwave arenavirus vectorbased immunization make fastest progress possible fight technologies hbv hiv scientific collaboration verily life sciences using lifethreatening diseases gilead finds ways build upon verilys immunoscape platform identify better understand immunologic basis complementary strengths accomplishments industry peers rheumatoid arthritis inflammatory bowel disease lupusrelated diseases collaborations acquisitions important part gileads growth strategy gilead plans pursue additional collaborations gilead executed partnership licensing deals completed equity investments biopharma companies collaborations provide gilead access new technology resources may enable rapid advancement oncology cell strategic collaborations investments therapy hiv liver disease inflammatory diseases collaborations oncology cell therapy included following industry innovators worldwide collaboration using sangamos zinc finger nuclease gene editing technology platform develop nextgeneration ex vivo cell therapies new cooperative research development agreement national cancer institute develop adoptive cell therapies targeting patientspecific tumor neoantigens strategic collaboration gadeta develop novel gamma delta cell receptor therapies research collaboration license agreement hifibio h h h therapeutics develop technology discovery neoantigenreactive cell receptors oncology global strategic collaboration tango therapeutics innovation fund pipeline targeted immunooncology treatments bioventuresfundworking gilead working gilead believe people woferaktinugr ea ts tgoirleyad working gilead different committed mission katie watson tara maccannell come different hear katie backgrounds gilead share vision work together tara means deliver lifechanging medicines patients around world part team believe celebrating others differences unique perspectives gilead visit employees make gilead company greater people sum parts employees notsosecret strategy gileadcomyir tackling worlds challenging diseases working gilead working gilead gilead offers employees unique opportunity combine professional advance ment continual learning ability impact local communities people around world challenge great contribution small inspire us act people bring spirit service everything advanced scientific research mentorship community engagement proud support workplace culture allows us bring best selves serve highest purpose reward recognize retain employees gilead offer competitive compensation programs well countryfocused people make benefits related health wellness retirement disability leaves absence total rewards program designed help attract cultivate retain difference industrys talented workforce offer employees financial benefits including base pay bonuses stock grant opportunities access variety health wellness resources timeoff benefits support training education assess benefits package year ensure place right offerings believe gilead inspired delivering lifesaving therapies patients help us attract retain critical talent total rewards package covers people need core values integrity inclusion teamwork accountability following core elements excellence cornerstones everything compensation financial benefits also committed creating promoting maintaining inclusive highper forming culture team members embrace leverage others tal gilead payforperformance company committed pay equity pay ents backgrounds sense shared purpose culture excellence employees based marketbased salary ranges pay decisions made without enable us reach millions patients around world turn tide seri regard personal characteristics gender race color national origin ous lifethreatening diseases ethnicity age disability sexual orientation gender identity gender expression working gilead working gilead genetic information religion veteran status gilead employees receive regular wellness offerings include biometric screenings wellness seminars onsite performance career development reviews monitor review employee fitness centers annual fitness reimbursement health assessment tools risk compensation annual basis ensure pay practices gender neutral benefits include sick days disability benefits companypaid life accidental death dismemberment business travel accident insurance gileads salary ratio expanded us health women men welfare benefits include applied united states behavioral analysis therapy fertility support employees financial benefits include employee assistance program eap services include financial legal retirement savings matching contributions available many countries preretirement elder care child care consultations well clinical counseling based local market practice regulations new online coaching tool provides us employees families access ondemand behavioral health support employee stock purchase program espp enables eligible gilead employees become stockholders purchasing gilead stock time discount consistent internal revenue service requirements believe detailed information gileads defined benefit plan obligations visit gilead offers competitive timeoff program help employees remain rested companys shareholder center website balanced throughout year timeoff benefits include companypaid vacation days people holidays vary country country based compliance local laws regulations common market practice health welfare benefits also offer familyfriendly leaves absence parental adoption leaves demonstrate commitment health wellbeing employees employees many countries including six weeks paid parental time ppto families offer marketcompetitive wellness extended healthcare risk benefits employees united states many countries working gilead working gilead worldwide gilead also supports continued employees employees parental leave returned education discount mba work end leave programs golden gate southern california university employees male female total participated onsite mba hold first week number employees entitled parental leave program foster city number employees took parental leave service number employees returned work leave ended giving together number employees retained months returning work following period parental leave gileads annual week service brings number employees took parental leave gilead launched giving together together employees around world return work rate program match make difference communities return work rate donations eligible nonprofit organizations october kite team southern retention rate per employee year california participated first week em rp el fo oy ree e l ln eo mt e pl li og yib el ee f ar r eb ten cd hin ng ic al le lya eve lig iba ley tr oe q tau ke es p ap er ns l e l ae va ev e absence spend time new child donated california fire service volunteers assembled care foundation wildfire relief fund los packages children receiving cancer angeles north valley community treatment los angelesarea hospitals professional personal development foundation chico california help decorated halloween parties boys affected northern southern girls clubs locations contributed g ileads learning development program fosters culture continuous california fires food drive westside food bank learning designed help employees develop crossfunctional skills tools grow careers learn culture employees families week service gave us chance believe evacuated wildfires work together provide little hope people gilead employees completed hours california greece hurricane michael smiles people need small professional management leadership development training florida typhoons asia offered gestures positive ripple programs average hours per employee paid time financial assistance help effect also help create bond cover cost hotel rooms meals local communities employees receive reimbursement tuition expenses incurred damaged personal belongings pursuing undergraduate graduate certificate courses lindy specialist cell therapy ii accredited college university annual reimbursement maximums eligibility may vary country country online courses assumed one hour working gilead working gilead volunteering communities gileads legal department spent approximately probono gilead aims positively impact communities hours representing clients work live connect variety areas including domestic talents employees unmet needs violence survivors asylum communities encourage worldwide immigrant juveniles veterans employees engage volunteer activities seeking medical aid benefit four core areas focus underserved communities education environment health awarenessoutreach worldwide hours domestic violence representation employees received additional paid day work volunteer organization choice hours immigrant representation part gileads second annual week service employees around world gave believe back local communities providing meals people maintenance habitat restoration care packages members military assistance foster city employees spent hours veteran community service hours supporting representation following six organizations pacifica beach coalition lifemoves operation care comfort working gilead working gilead boys girls clubs oakland working demonstrate commitment commitment glide inclusion requires us larkin street youth services lgbtq encourage employees southern california participated week support community service first time volunteering three nonprofit organizations supporting recognize mitigate youth families los angeles area unconscious bias honoring diversity makes us consider multiple effective workforce helps us better pathways success understand serve patients around welcome respect people world natural started backgrounds experiences developing treatments diseases disproportionately affect lbgtq celebrate diverse seek diverse perspectives community fiercely committed drive innovation supporting lgbtq employees today perspectives advocating transgender rights marching pride parades around formed world hosting honest conversations gilead expands new therapeutic areas geographic regions business diversity council inclusion diversity gilead stands becomes increasingly complex building inclusive diverse workforce helps lgbtq employees takes chaired senior us evolve along business ultimately better serve patients pride difference make believe generating greater diversity thought accelerate innovation amplify management communities productivity achieve mission improving patient care meeting unmet people measure ability medical needs around world varied perspectives experiences attract develop help drive innovation us gilead diversity gilead means recognizing accepting ways differ committed promoting inclusion retain employees includes visible differences age gender ethnicity physical appearance diversity simply right thing well underlying differences thinking styles religion nationality veteran diverse backgrounds daniel o'day chairman ceo status sexual orientation sexual identity education gilead added inclusion core value better help us build community accountability working gilead working gilead new diversity council track progress relative following improvement goals amplifying gilead asian interest network gain employees voices gain unites asian employees increasing transparency diversity data allies deepen cultural understanding across company listening employees crucial implementing tracking diversity action plans specific different organizations regions continued success especially continue evolve obtain valuable insights gilead leadership organization black building inclusive culture integrating expanding employees periodically issue workplace employees globe unconscious bias trainings globally launching multicultural tools surveys covering multitude topics including globe works cultivate improve team effectiveness across borders leadership among people core values impact innovation career african descent advancing opportunities people development inclusion engagement work valued environment collaboration efficiency creating communities gilead women gilead global network women gilead boosts many employees participate employee resource groups ergs recruit develop support female employees groups provide opportunities leadership development community involvement worldwide employees thrive future networking mentoring skills advancement participating recruitment diverse provided valuable candidates ways gilead employees make difference beyond lgbtq alliance usual work responsibilities feedback helping lgbtq alliance keeping gilead place shape business gender diversity members chapters around world gileads celebrated community prioritized people feel ergs helping us scale inclusion diversity initiatives creating sense strategy moving forward empowered belonging employees believe gileados received top score human rights campaign hrc gileados members embrace espouse appreciation people corporate equality index cei national benchmarking tool corporate policies multifaceted latino culture gilead goal practices related lesbian gay bisexual transgender lgbtq employees enhancing recruitment retention diverse talent recognition diversity inclusion efforts forbes named gilead one gilead veterans engagement best employers diversity team gvet gvet plays important role recognize appreciate support veterans active duty military families working gilead working gilead results survey reflected positive feedback several categories including core values impact innovation career development time employees identified opportunities improving collaboration operational efficiency inclusion diversity initiatives response feedback formed action teams late evaluate opportunities take action spirit creating community accountability action teams meet quarterly report progress respect improvement opportunities improvement opportunity action implemented organizational network analysis ona map connections employees collaboration understand improve crossfunctional crosslocational collaboration unveiled new work schedule options increase efficiency flexibility around employees work formed diversity council created inclusion diversity organizational diversity action plans enhance believe diverse hiring development programs people working gilead working gilead global workforce united states gender age raceethnicity distribution gileads worldwide staff grown people still strive make workforce close community everyone see tangible results contributions every individual matters everyone chance enhance skills ongoing development people numbers people numbers us gilead continually looks opportunities diversify workforce data important part process year review total new hires voluntary turnovers gender race ethnicity metrics following snapshot gileads workforce demographic data gender raceethnicity worldwide new hires voluntary turnovers black believe african hispanic eeo category male female white american latino asian people new hires executives new hire rate firstmidlevel managers voluntary turnovers professionals voluntary turnover rate total gilead us population new hire data includes individuals hired externally existing employees changed positions internally included calculation working gilead working gilead building culture workplace safety gilead believes safe secure workplace inspires innovation promoting health wellness productivity workplace safety training security program designed prevent occupational injuries illnesses promote culture reporting safety measures include tailored training sessions annual refresher courses detailed assessment incidents nearmisses worldwide frequent workrelated injuries musculoskeletal extremity back neck strains caused material handling ergonomic slip fall motor vehicle hazards ergonomics trip hazard led two highconsequence injuries individuals unable recover fully within six months executive management meets quarterly review environmental safety performance across sites joint managementline health safety committees review sitelevel performance teams complete indepth reviews individual sites incidents occur identify causes determine keep similar events happening future gilead workforce data believe fte nonfte employees number fatalities result workrelated injury people rate fatalities result workrelated injury number highconsequence workrelated injuries rate highconsequence workrelated injuries total number recordable workrelated injuries rate recordable workrelated injuries rates calculated based hours worked fte nonfte eg temporary workers managed directly gilead consistent usosha record keeping requirements data reported us authorities internally number highconsequence workrelated injuries based lost timedays away restricted workday cases reported osha community impact community impact believe one alone cofmematuunriet ys itmoprayct community impact aging hiv 're managing new challenges years hiv community pushed boundaries broken barriers campaigned positive change first generation people hiv enters later life new unprecedented challenges emerging many historic challenges remain launched uk gileads hiv age positively aims address greatest challenges aging hiv taking action today learn gilead tomorrow believe hiv age positively visit one hiv age positively embraces ethos thinking things gileadgivingcouk alone differently provide innovative ideas fresh perspectives work future thinkers individuals known groundbreaking work inside outside hiv space hiv age positively initiative gilead provides funding projects inspired thinking things differently focus one hiv age positively key focused areas community action personal health equality health services community impact community impact providing access medicines effective treating preventing curing disease medicines must available patients need access medicines programs gilead expanding access treatment helping patients overcome barriers get medicines need obstacles care occur resourcerich countries developing world alike gilead collaborates governments nongovernmental organizations healthcare providers payers partners around world believe increase access treatment one alone community impact community impact access medicines patient assistance programs eligible patients without insurance apply patient assistance program receive free treatment directly united states gilead us healthcare landscape complex difficult navigate ease burden place patients caregivers gileads patient assistance expanded access program programs help provide access medicines copay assistance counseling across therapeutic areas accordance applicable laws people serious lifethreatening conditions arent eligible clinical trials therapeutic options available meet addition discounting programs aimed addressing affordability challenges needs gileads expanded access program offers access investigational patients gilead pursuing creative solutions challenges instance medicines program varies regionally result unique regulatory mech gilead authorized launch generic versions epclusa harvoni anisms worldwide since investigational medicines yet received regulatory united states starting january separate subsidiary asegua approval potential risks benefits yet established patients therapeutics llc authorized generics allow greater access patients physicians must carefully consider possible benefits risks seeking ac cess compassionate use gilead patient support programs rapid access medications program patient counseling case managers help patients navigate insurance coverage access treatment assistance includes finding alternative coverage copay gilead also recognizes extreme weather events threaten health systems support appropriate interrupt access care effort prevent interruptions patients treat ment gilead medicines continental united states territories believe assistance individuals living hiv gilead works state implemented emergency disaster procedures patient support programs one aids drug assistance programs provide lower pricing hiv medicines gilead works healthcare providers pharmacies help provide prescribed alone approximately half individuals taking gilead hiv medicines united states gilead medications patients need individuals may eligible obtain receive federal state programs substantially discounted prices day replacement supply gilead medications cost gileads truvada prep medication assistance program helps provide access truvada prep eligible individuals united states without insurance gilead also offers copay assistance program help eligible people insurance offset outofpocket costs program provides consistent access prevention treatment indications community impact community impact tiered pricing discounts medicines based disease burden national percapita income responsible generic licensing products enable highquality lowcost versions hiv viral hepatitis medicines low middleincome countries advocacy public health initiatives policies maximize patient reach prevent new infections strengthening health systems bolster diagnostic treatment surveillance capacity collaborative research targets innovative therapies informs drug delivery helps countries map disease burdens information initiatives improve global access lifesaving medicines public health education refer impact report emerging markets access medicines developing world giving back years gilead carried pioneering programs believe partnerships provide access medicines low middleincome communities one countries time learned onesizefitsall solution alone treatment access challenges gilead know alone solve challenges patients thats work public health officials community advocates researchers communities face accessing best possible care gileads corporate giving doctors patients understand barriers opportunities focus programs fund projects support underserved communities systematically communities impacted hiv viral hepatitis visceral leishmaniasis apply experience social economic obstacles health build relationships patient variety approaches increase disease awareness engage partners strategically advocates nonprofits healthcare professionals around world work tirelessly deliver medicines efficiently include local communities improve peoples lives day day community impact community impact gilead provided almost million cash donations reduce health disparities eliminate barriers healthcare encountered underserved populations advance education among healthcare professionals support local communities tm operate also made donations support relief efforts communities recovering wildfires california hurricane damage eastern united states flooding india outbreak ebola democratic republic congo helps communitybased organizations reduce hivrelated health gilead compass initiative disparities build awareness advance education reduce stigma south home onethird us population saw new hiv infections deaths hiv country four five states highest rates new hiv diagnoses south bring compass coordinating centers solutions hardesthit region gilead launched compass commitment partnership addressing hivaids southern states initiative december delivered million grants support compass managed three coordinating centers draw long local organizations evidencebased history local engagement effectively understand develop programs solutions meet needs people living meet unique needs southern communities impacted hivaids rollins school public health emory university oversees programs capacity building shared knowledge believe one promoted visibility program university houston graduate college social work gcsw alone oversees programs focus wellbeing mental health advocates six conferences traumainformed care throughout region southern aids coalition sac oversees awareness education antistigma campaigns hosted shared learning opportunities designed foster collaboration best practices connection subjectmatter experts community impact community impact partnerships advance education improve cancer care gilead launched lift initiative provide project grants organizations focused cell therapy cuttingedge immunotherapy modifies patients immune cells target cancer cells lift grantees include american society blood marrow transplantation arm foundation regenerative medicine education research match foundation cancer support community lazarex cancer foundation believe one leukemia lymphoma society alone lymphoma research foundation lift grants used projects increase awareness education improve experience patients families caregivers increase access clinical trials practices environment practices environment believe business sustainable practfiecaetsu r ee nsvtoirroynment practices environment caring environment james oregan mission positively impact community reducing gileads footprint sustainability manager james cork team manufacturing facility cork ireland hes keeping things green visit last year cork marked sixth consecutive year zerowaste gileadcomyir believe facility running renewable energy business sustainable practices environment practices environment smarter green buildings gilead smaller footprint buildings house laboratories develop medicines help millions people around world live healthier lives embracing core sustainability gilead committed socially environmentally responsible green building practices conserving natural resources eliminating unnecessary waste responsibly sourcing materials enabled us better production medicines help people living worlds deliver highperformance working environments operate efficiently promote serious illnesses health productivity employees years developed worldwide sustainability strategy built partnering building designers engineers contractors share initiatives reduce impact associated supply chain manufactur commitment sustainability adds value phases development ing distribution products design construction operations process also streamlines efforts align local green building standards worldwide corporate facilities including leadership energy environmental design leed building research establishment environmental assessment method breeam past years gileads real estate portfolio grown million square feet use responsible growth strategies minimize environmental gilead began taking steps toward leed silver certification new site impact improve operational efficiency pursuing vision advance frederick maryland breeam certification new site hoofddorp therapies lifethreatening diseases worldwide netherlands sites expand gileads portfolio facilities either believe international facilities master plan valuable resource thoughtfully manag pursuing achieved green building recognitions ing infrastructure real estate decisions business sustainable gilead part transition lowcarbon future mitigate effects climate change line paris agreements central aim keeping global temperature rise degrees celsius century estab lished goal reduce global scope greenhouse gas emissions compared baseline practices environment practices environment gilead site highlights responsible delivery systems foster city california united states start electricity supplied worldwide gileads pharmaceutical development manufacturing pdm team responsible headquarters sourced renewable energy ensuring therapies available patients need renewable energy procurement efforts foster city cork ireland demonstrated use combination companyowned facilities expanding network reduction scope emissions achieving half ghg reduction goal procurement efforts expanded foster city international partners manufacture package distribute products edmonton alberta canada iso meet growing demand innovative medicines areas unmet need recovering highpurity wastewater laboratories cool vacuum pumps onsite constantly working optimize diversify manufacturing capabilities save million liters freshwater per year viread tenofovir disoproxil fumarate tdf launched gilead produced stockley park england bottles one manufacturing site equivalent years supply stockley park eliminated use plastic water bottles site avoiding patients gilead produced million bottles soliddose tablets waste singleuse plastic bottles per year capsules pediatric formulations million sterile vials manufactured dozen partner sites worldwide driven growth activity newly built facilities total energy consumption increased baseline however time investments increase manufacturing production committed socially procuring lowcarbon sources energy reduced worldwide scope market environmentally responsible manner gileads suppliers active pharmaceutical based greenhouse gas emissions gilead actively looking opportunities ingredients apis drug products must observe good manufacturing practice increase proportion energy derived renewable sources gmp regulations required us food drug administration fda relevant health authorities worldwide gmp covers aspects production environmental performance summary including manufacturing procedures testing methods maintenance premises units equipment training personal hygiene staff appropriate documentation believe total area facilities worldwide operational control million sq ft maintain highest levels quality products packaged distributed business sustainable energy use accordance industry regulations standards regularly assess total energy consumption mwh operations identify opportunities enhance processes without renewable energy purchased mwh compromising quality greenhouse gas emissions scope mt coe end gilead consolidated product shipments sites san scope marketbased mt coe dimas la verne california distribution centers midwest east coast reducing annual ground freight mileage restatement square footage value reported pg year review refer disclosure gri content index additional details practices environment practices environment gilead began utilizing new distribution site ohio strategic location pharmaceuticals environment facility substantially reduces shipping distances products packaged manufacturing partner sites midwest eastern united states provides pharmaceuticals environment pie serious health consequences additional product storage capacity helping mitigate potential supplychain people wildlife pharmaceuticals typically reach environment disruption risks excretions treated patients improper disposal medications releases production facilities local water sources gilead 's manufacturing facilities maintain high operational standards release better yields green chemistry active pharmaceutical ingredients environment adhere strong internal policies operate compliance regulatory requirements wastewater discharge gilead uses green sustainable chemistry practices reduce environmental solid waste disposal impacts manufacturing processes process chemists develop implement new green chemistry protocols innovative use enzymatic gilead member pharmaceutical product stewardship work group ppswg catalysis flow chemistry use greener solvents api synthesis green membership association drug manufacturers formed address complex issues chemistry practices allowed us associated disposal unused unwanted pharmaceutical products ppswg provides members platform organize present sciencebased data improve potency apis significantly reduce chemical waste safe pharmaceutical disposal practices coordinates industrys efforts raise production biktarvy single tablet regimen launched treatment awareness appropriate disposal methods ppswg also helps manufacturers hiv understand comply enacted drug takeback stewardship laws ordinances nationwide significantly reduce process mass intensity pmi two investigational compounds currently development ppswg gilead supports consumerfocused drug takeback stewardship believe efforts medproject performs medication education disposal work pmi green chemistry metric used quantify efficiency process pmi jurisdictions across country gilead contributed support med business represents mass process inputs substrates reagents solvents sustainable project takeback efforts december medproject serviced approximately water divided mass isolated product pmi entire api active medication disposal kiosks collected metric tons process route analyzed evaluate contribution input category unwanted medications medproject received unwanted medical mailers substrates reagents solvents water analysis used identify opportunities distribution programs california washington held inperson drug takeback improve api manufacturing processes events san francisco alameda county california collected metric tons unwanted medications practices environment practices environment gilead joined american use child labor unfair treatment wages benefits working hours improving drug potency chemical society green chemistry forced labor human trafficking discrimination based race color gender using green chemistry institute pharmaceutical roundtable religion disability sexual orientation gender identity expression also support techniques reduced acs gcipr member gilead full compliance applicable legislation including united kingdom modern chemical waste associated involved development antislavery act api manufacturing tools educational resources biktarvy per patient per facilitate global collaboration responsible sourcing program year compared stribild influence pharmaceutical industry gileads previous generation research agenda gileads responsible sourcing program builds relationships suppliers meet hiv fixeddose combination criteria inclusion diversity health safety human labor rights anti tablet containing four corruption environmental performance supplier management considerations working drug substances suppliers single mg tablet biktarvy three pillars responsible sourcing api potency mg share tablet stribild eliminates gilead suppliers must align core values meet financial performance kilograms chemical production values criteria order qualified business gilead waste per patient year ensure consistently gilead hiv single tablet regimens providing highest quality therapies partner suppliers share annual chemical waste produced believe similar principles responsible kgpatientyear sourcing supplier inclusion risk business sustainable management sustainability auditing risk mitigation sustainability stribild green chemistry manufacturing supplier inclusion performance ghg emissions distribution across supply chain inclusion small andor esg risk financial risk environmental impact diverse suppliers geographic risk supplier code green procurement vehemently oppose condemn biktarvy practices environment practices environment pursuing inclusive procurement supplier inclusion sharing best practices western regional minority supplier development council group vision become biopharmaceutical supports growth welfare minority communities championing industry leader supplier inclusiveness use minorityowned businesses northern california nevada hawaii inclusion diversity fuel innovation within gilead also help us forge stronger risk management performance productive supplychain partnerships vision become biopharmaceutical industry leader supplier inclusion committed creating fostering inclusive gilead longstanding member drug insurance group dig highperforming supply base embrace leverage unique talents small consortium global companies representing pharmaceutical biotech businesses andor businesses owned women minorities lgbtq individuals veterans diagnostics medical device industries exchange information ideas servicedisabled veterans promote risk insurance management established following inclusion targets gilead launched threeyear responsiblesourcing strategic plan enhance supplier risk management performance assessment reporting spend million small businesses auditing procurement integration efforts establish supplier inclusion champions select business functions integrate supplier inclusion procurement processes procedures initial assessment supplier reporting expand audit system integration help us build capacity grow relationships inclusive suppliers initial assessment implement expand responsible sourcing believe suppliers selfassessment selfassessment fully integrated partnered following organizations supplier tool send top audit including buydesk code psci secondary critical suppliers supplier onboarding business critical suppliers srm sustainable diversity alliance science alliance identifies small andor diverse businesses gilead industry peers partner integral plan supplier code conduct establishes minimum requirements supplier diversity labor practices human rights environmental supplier diversity pharmaceutical forum forum members dedicated health safety environmental impact management systems aim suppliers annual spend agree supplier code driving business results innovation agility performance conduct mentoring developing small diverse suppliers practices environment practices environment end suppliers representing continually monitor supply chain adequate capacity diversification potential risks adherence gilead policies governing regulations close billion annual spend agreed foreign corrupt practices act fcpa us trafficking victims protection act supplier code conduct tvpa applicable labor environmental regulatory policies refer ethics code conduct section website information supplier sustainability evaluate address risk ethical violations countries involved supply chain help improve sustainability performance supplychain partners joined pharmaceutical supply chain initiative psci goal encounter actual potential violations company policies governing preferred suppliers align psci guidelines sustainability targets regulations recommend corrective action flag supplier followup place regularly reviewed plan initially work select suppliers evaluations certain violations use forced labor human trafficking establish greenhouse gas ghg reduction targets plan expand environmental negligence would lead gilead terminate agreement process include larger share suppliers future supplying organization remove supply chain auditing procedures safety ethics transparency gileads environmental health safety ehs auditing program drug substances conducted onsite audits ehs visits unique gilead adheres strict product safety labeling marketing data security anti suppliers since program established counterfeiting guidelines products undergo rigorous development testing site visits audits determine extent chemical raw materials clinical trials use labeling marketing practices pursuant governing believe policies regulations gilead receive official warnings fines manufacturers suppliers finished apis meet gileads ehs standards penalties related marketing labeling practices business practices including capture volatile organic compounds chemical solid waste sustainable disposal solvent recycling compliance local international standards protect personal data use combination inhouse technology third party security services systems comply data protection regulations assessment risk mitigation auditing procedures continually european union general data protection directive substantiated evolving ensure products consistently produced controlled complaints concerning breaches customer privacy losses customer data according quality standards gmp work closely suppliers identify practical improvement areas share best practices reducing anticounterfeiting team consists brand protection legal security supplychain eliminating risks quality packaging professionals protect patient safety using measures help detect stop deter report illicit sales counterfeit diverted medicines practices environment practices environment greenhouse gas prevention sustainability year measure scope ghg emissions resulting business climate change activities worldwide scope emissions associated business travel report gileads greenhouse gas reporting boundary includes sites gilead maintained operational control jan dec environment bureau veritas north america inc completed limited assurance using international organization standardization iso standard greenhouse gas assertions global health gilead publish verified worldwide greenhouse gas inventory data available climate change intensified greenhouse gas ghg emissions threatens ghg reduction initiatives health populations environments worldwide often populations impacted effects climate change underserved communities baseline year measuring ghg reductions first year tracked gilead provides medical care lifethreatening medical conditions scope emissions sites operational control hiv viral hepatitis visceral leishmaniasis gilead established target reduce impact climate change underserved atrisk populations important absolute scope marketbased ghg implications global health include increased transmission serious believe diseases compounding health risks young elderly greater danger emissions compared already immunocompromised global citizens providing care gilead business baseline sustainable stands patients atrisk populations environment ambitious ghg strategy meet goal line paris agreement 's central aim keeping global temperature rise degrees celsius century developed multiyear plan includes procuring renewable energy highimpact locations applying energy efficiency technologies measures improve performance facilities practices environment practices environment gilead reduced absolute scope marketbased ghg emissions scope ghg emissions gilead worldwide operations metric tons carbon dioxide equivalent mt coe equivalent reduction baseline emissions reporting units mt coe scope scope marketbased scope locationbased reporting units mt coe scope business air travel baseline goal scope scope marketbased scope locationbased rsecpoopret ing b uunsiitnse sksg aciro traev epler square foot scope ghg emissions intensity scope marketbased scope locationbased reporting units kg coe per square foot scope current year reduction target pace scope marketbased scope locationbased believe business sustainable practices environment practices environment alternative transportation energy use gilead proactively supports employees finding alternative lowimpact means gileads energy management strategy supports lean effective highquality transportation variety programs initiatives including therapeutic development optimized processes facility operations realized major reductions energy footprint investing providing local regional commuter bus services campus renewable energy implementing energyefficiency measures adopting supporting carpool programs subsidies incentives advanced energy processes locating offices near public transit start procured renewable electricity headquarters installing electric vehicle charging stations campus foster city california achievement represents major milestone encouraging bicycle transportation installation showers toward meeting greenhouse gas emission reduction goal foster city joins within facilities partnering bicycle service providers campuses cork ireland cambridge uk sites procuring installing green energy foster city transportation metrics worldwide energy consumption year track total energy use nonrenewable sources renewable energy generated onsite systems purchased local utilities also track energy use intensity evaluate efficiency building portfolio grows believe business compared baseline year total energy use increased due sustainable organic growth organization including activity newly built sites commuters transported gileads metric tons coe emissions employee bus per day reduced employee vehicles commuter bus program practices environment practices environment worldwide energy consumption better water management energy energy use beginning united nations called international decade action consumption intensity energy source mwh kwhsqft water sustainable development call action identifies access clean drinking water sanitation hygiene critical societal needs prolonged total energy consumption renewable sources droughts california many regions around world gilead total energy consumption nonrenewable sources operations increased focus water conservation total combined energy consumption energy efficiency december gileads foster city campus completed comprehensive upgrade smart building energy efficiency key driver reducing worldwide energy consumption facilities personnel continuously monitor building energy use weatherbased irrigation controllers identify trends pinpoint opportunities energy conservation commitment renewable energy strongly supports mission gain better understanding worldwide impact water supplies reduce worldwide environmental footprint expanded water use reporting boundary headquarters campus foster city california include sites operational control andor pay gilead implemented energy efficiency projects worldwide water directly gilead consumed ml water municipal sources achieving estimated total energy savings mwh electricity supplied gileads facilities located foster believe city california cork ireland sourced renewable energy worldwide water consumption business sustainable onsite rooftop solar photovoltaic system cambridge capable water source megaliters generating kwh renewable energy per day indoor use irrigation firelife safety total water consumption practices environment practices environment increased recycling efforts worldwide waste disposal committed reducing waste generated manufacturing products nonhazardous waste disposal metric tons constructing new buildings operating existing facilities worldwide reduce landfill impact local landfills continuously monitor operations identify opportunities organics reduce reuse recycle waste reduced total waste sent recyclables landfills foster city headquarters incineration late expanded waste reporting boundary foster city campus total include worldwide sites operational control andor pay waste disposal directly generated metric tons nonhazardous waste metric tons hazardous waste serve baseline year future hazardous waste disposal metric tons comparisons incineration hazardous nonhazardous waste streams picked facilities energy recovery transported local processing facilities thirdparty vendors must comply ewaste recyclables local regulations onsite storage neutralization solvent recovery collective impact metal recovery recovery reuse waste reduction recycling requires team effort gilead support deepwell injection believe worldwide staff diverted metric tons nonhazardous waste landfill business local landfills total sustainable september gilead foster city hosted shred ewaste event collecting metric tons paper electronic waste recycled construction waste new pilot plant foster city diverting metric tons debris local landfills appendix appendix appendix governing principles gilead company driven science dedicated improving patient care quality life gilead adheres highest legal ethical standards business conduct gilead sciences inc leading biopharmaceutical company discovers protect patient safety company employees develops commercializes innovative medicines areas unmet medical need strive transform promise science technology therapies gileads board directors serves stockholders overseeing management power cure diseases revolutionize standard care gileads portfolio business board leadership team employees gilead products pipeline investigational drugs include treatments hiv liver responsible upholding corporate values integrity inclusion teamwork diseases cancer inflammatory respiratory diseases excellence accountability addition every gilead employee must comply code ethics antibribery anticorruption policy well headquartered foster city california gilead employed fulltime employees business conduct corporate policies engaged temporaryagency workers countries six continents board four committees audit committee compensation committee nominating corporate governance committee scientific committee board guidelines committee charters found investors website listing rules require majority members public companys board directors qualify independent committees composed individuals employed engaged agency worker thirdparty temporary agency compensated independent board members march upon daniel odays appointment perform work gilead predefined timeframe john martins resignation eight nine members independent appendix appendix code stand approach csr gileads governance bodies employees must comply code years gilead discovered developed expanded access ethics antibribery anticorruption abac policy corporate bestinclass therapeutics treat lifethreatening illnesses ensure policies available gnet company intranet accessible continue execute mission future reducing social managers employees abac trainings provided environmental impacts resulting business activities built employees contractors audit committee subset board corporate social responsibility csr program focuses patients society directors regional business partners distributors located asia north planet business america south america objective reduce impact climate change foster better communities success gileads code ethics depends upon employee compliance attract retain toptier employees mitigate supplychain risks prepare relevant laws rules regulations associated employment including laws future regulatory changes prohibiting insider trading assembled csr committee shepherd vision build assess adequacy key corporate policies annually help ensure accountability driving positive social environmental change across consistent current regulations good governance practices company supply chain leaders human resources legal operations public affairs responsible reviewing making decisions csr products distributed throughout world gilead affiliates others related strategies stakeholder engagement reporting risk mitigation acting gileads behalf required comply applicable anticorruption relevant activities gilead subsidiaries least annually csr committee laws laws include united states foreign corrupt practices act fcpa provides report nominating corporate governance committee uk bribery act applicable laws gilead offers training materials gileads board directors employees relevant individuals organizations communicate gileads prohibition corrupt unethical activity csr management stakeholder gilead performs internal external audits monitor compliance regulatory engagement materiality company policies audits performed roughly countries financial fcpa compliance gilead uses companywide management approach continuously monitor internal external material impacts purpose reducing potential actual findings corruption healthcare compliance negative impacts associated company operations business leaders direct violations government body oversight topic area responsible managing impacts internal appendix appendix external stakeholders evaluate material topics effectiveness gileads management center approach year identify strengths corruption compliance state federal international laws pertaining areas improvement bribery healthcare fraud abuse political drug safety recalls adverse events providing relevant information efforts accountability every three years evaluate csr anticounterfeiting counterfeiting management approach stakeholder providing access products around world including efforts ranking engagement process material impacts access pricing ensure fair pricing maximize effectiveness charitable efforts aimed reducing disparities providing access giving companywide csr program last advancing medical education supporting local communities stakeholder engagement materiality efforts eliminate serious accidents manage occupational employee health exercise occurred health safety risks ensure employees come harm gilead scored safety work employee wellness efforts promote employee wellness development internal stakeholders development engagement employee benefits wellbeing recruiting engagement retention internal stakeholders representing inclusion efforts promote inclusion diversity th place corporate communications corporate diversity cpazicklin index corporate contributions access operations climate change reducing greenhouse gas emissions associated company emerging markets pharmaceutical energy operations products using energy efficiently political disclosure development manufacturing global ethical sourcing ensuring suppliers uphold appropriate standards accountability analyzes commercial commercial process ethical supply chain corporate responsibility issues transparency corporate optimization environmental health manufacturing managing quality production capacity inventory manufacturing political spending large safety facilities human resources supplychain supply chain management legal tax investor relations us publicly held companies design chemical products processes reduce eliminate regulatory affairs engaged discuss green chemistry ranking earns us toptier generation hazardous substances sustainabilityrelated topics trendsetter mark among responsible efforts ensure marketing conducted ethically complies marketing local laws regulations sp waste hazardous nonhazardous waste recycling water efforts manage reduce water use operations year review appendix appendix un un reporting disclosurea description reference sdg gc boundary year review gri general disclosures gri content index external stakeholders gri content index gilead employees austria belgium brazil collective bargaining agreements spain percent worldwide workforce subject collective bargaining agreements un reporting disclosurea description reference ungc gileads external stakeholders included stakeholder groups across following sdg boundary four categories gri general disclosures identifying selecting stakeholders name organization appendix gilead p appendix csr management stakeholder engagement p business leaders across company selected following material topics approach stakeholder engagement materiality activities brands products services science innovation science driving p csr program based extent gilead internal external influence key topics concerns raised location headquarters relative impact peer evaluations due diligence entities included consolidated appendix gilead p lfioncaantcioianl ostfa otpeemreantitosn p purpose report od bwoe uf ni nn edi rn sag hr iier pe p drt lc eo gn le fn ot r man topic g coil pa od r tc ioie nn ces inc publicly traded delaware mliastr koeft ms saetervrieadl topics aa af mnpr dip ec ea rmin c ada ati ex ai ra n ic las istru yos utr taa hnl aaa mg ee eum rr icoe apn et smtaidkdelheo eldaesrt e nnogratghe ment p banks global insurers ngos purpose looking p csr ratings regulators scale organization total square footage corporate facilities reported restatements information p year review corrected indices aopnp pendi xof athbeo ut gile yaeda r review p worldwide academic institutional institutions win ofo rkrm era st ion employees appendix gilead p investors changes reporting analysts investors rulemakers media supply chain poruarc tpicuerps os een avibroonumt tehnist r reepsoprot nsible delivery systems pp risk watchdogs reporting period assessors worldwide stockholders industry significant changes organization practices environment responsible delivery systems p associations idtsa steu popf lmy cohsat irne cent report may healthcare partners p rr ee pc oa ru tt inio gn ca yry c lp er inciple approach ap np ne un ad l ix approach csr p providers customers peers e cx ote ntr ca tl pin oit inia tt fv oe r q uestions regarding ko ou rr p bu zr ko e v ia cb eo pu rt e sh idis e nr te p po ur bt lic affairs p insurance peers community business report csrgileadcom providers partners memberships associations science innovation partnerships p suppliers claims reporting accordance purpose report p patients gri standards statement senior decisionmaker purpose ceo letter p communities generic drug gri content index gri content index p manufacturers values principles standards norms appendix governing principles p disclosures refereenxctee grnria l ass sutraanndcaerd reporting period opfr jaacnti ce e ton vdierocn nt g urneleesnsh thoeu dsies cgloassu rpe ries vmeanrktieodn w ith b c p b disclosure references gri standards c reporting period covers jan dec includes worldwide sites gilead maintained operational control andor paid utilities directly executivelevel responsibility economic appendix approach csr p environmental social topics appendix csr management stakeholder engagement p aall disclosures refleisret nocfe gtarkie holde sr tgarnoduaprdss reportinagn pde mrioadte orfia jlaitny dec unless disclosure marked b c bdisclosure references gri standards creporting period covers jan dec dincludes worldwide sites gilead maintained operational control andor paid utilities directly aall disclosures reference gri standards reporting period jan dec unless disclosure marked b c bdisclosure references gri standards creporting period covers jan dec dincludes worldwide sites gilead maintained operational control andor paid utilities directly year review gri content index disclosurea description reference un ungc reporting year review sdg boundary gri general disclosures name organization appendix gilead p un un reporting disclosurea description reference sdg gc boundary activities brands products services science innovation science driving p gri general disclosures location headquarters appendix gilead p location operations gilead employees austria belgium brazil collective bargaining agreements spain percent worldwide workforce subject ownership legal form gilead sciences inc publicly traded delaware collective bargaining agreements corporation africa asia australia europe middle east north markets served year review america south america identifying selecting stakeholders appendix csr management stakeholder engagement p purpose looking p approach stakeholder engagement materiality scale organization un un reporting appendix gilead p disclosurea dkeeys tcorpipictsi oannd concerns raised reference sdg gc boundary wn ofo rkrm era st ion employees appendix gilead p gri general de fiisnn cat li onti cse uis ar li e n ssc alu td emed e nin st consolidated p purpose report defining report content topic supply chain practices environment responsible delivery systems p boundaries gilead employees austria belgium brazil worldwide collective bargaining agreements spain percent worldwide workforce subject significant c hanges ythee oargra niinza tirone anvdi ew list material topics taop cpoelnledcitxiv ec sbra rmgaainnaingge magernete msteanktesh ionl der en gagement p supply chain practices enpviropnmeennt rdespioxnsible delivery systems p materiaalityp pendix precautiona ry princip ley oer aapprr oianch r evieawpp endix approach csr p identifying select inyg estaakre hionld errs evietwhe total square footage corporate facilities reported c losurea ed xe tes rc nr ai lp ni io tin ives r oe uf pr ue rn pc ose e report su dn g u gn c pa pg e r op uo nr dt rg ar pe pst ra ot ae cm tn ot ss af k ein hf oo lr dm ea r eio nn g agement ao onpn ndp p p e n ad eox orf f ct ath hls ie etr n yge eea amr r ien nn r rte e sv vit iea ewk hh aosld beere enn cgoargreemcteendt p worldwide ggrri c goenenralt diesclnosutre si ndex gri contkeey ntoptics iannd dconecexrns raised memberships associations science innovation partnerships p changes reporting disclosurea description ralel fgeilreeandc eem ployees austria belgium brazil su dn g ungc r op uo nr dt rg disclosurea e fdinn eati snti cce irs ai pli n stc tioalu tnd e med e nin st consolidated roeurf epruerpnocsee report su dn g ungc ppp ge r op uo nr dt rg sctoaltleemcteivnet bfraormga sineinnigo ra dgereceismioennmtsa ker ospuar ipnu rp poeserc ecneto fl wetoterlrd wide workforce subject p reporting period purpose report gri general disclosures collective bargaining agreements g r general ddisecflionsinugre rse port content topic boundaries name organization appendix gilead p name organization appendix gilead p date recent report may values principles standards norms appendix governing principles p appendix csr management stakeholder engagement aidcetinvtiitfiyeisng b aranndd sse lpercotidnugc ststa aknedh oseldrevircse science innovation science driving p laicstti voift imesat berraianl dtosp picrso ducts services asncdie nmcaet er iianlnitoy vation science driving pp year review reporting cycle annual appendix csr management stakeholder engagement laopcpartoioanch tfo h estaadkqeuhaorltdeerrs engagement materiality p location headquarters g ri c l u gr ee n ea r al dl oe e ldk e f iio ix n snne w see ccv aty tni l sc nt oor eiu co ce sfi rt r si aiv n rtpi h lice ea nio stse p k sci tl fn e e aa l auot htv n n na epe od l mee l l c drr l ena ee eo nidt gs rn ni tp ac g ss en l h ro ofn rs ec us ra ci pmb ol sr n l oi st spy oe lf c io ds r e tec nomic aa g cr oo np pp ie ul r dep pp rf p aee ee pmodn nn r ur ae dd rs pti ii n ecx xx ooi rc e sno ca aen e lb su c rr e u bmtp agp n unir c tl ao e gaa hs ecd h sa rt p eo eu n pc b ols rcr ttl ay kt era hd oe ldd e r e el na gw aa gr ee ent su dn g u g n c p pp pp g e r op uo nr dt rg rl oc r c geoeo l rwapcsn iinoat mt sa erta titt sr aoc e nn om h p fio e po arfn e ri dt ps nt p f oe ro tfr lir eni nq ggifu ie n lnr fms oat rco mt cn oo rn dr e ag na cr ed win ig th h e oa g ck c oh osn nop ulre r r ep rp p pa aet pob go dn ur dz al ra se pu ti ol cx ia ok ofs e sq nta th n ehu cb e c v eoa e mr cu se f ig op n u oir c tl ye e yt te ea hsagid ad sar e rnon pn e tf u r r pc bep eo olvu ivr rcipb tie le yol wi w cr r ha ae dff eaf dbirc es di el et ni le acs wo r r ae r rep eco tr et de p p worldwide md boe auf ri knn edin tasg r iser ee srp vo er dt content topic af mri eca ri c aia n su os utr ta hl aa e eu rr ico ap e middle east north c mgh raa ir n kceg ote nss es enn r r v ie enp ddo er xt ing year revie oa agw f murr ri iec cpa riuo c rna apt aoeia nsne dt snau ods buet txa uh l tm h e iesu r rr ico eap p e r iddle east north pp gilead employees austria belgium brazil reporting period isclosures refscl ei c ros ealt nl le eo cc ef mi gfv tae rht ibe e r oi ra rg l g aoi n n spi tni z ac ag ns ia ag rnr e se nde n ht v e reportin ga aoo npp p uda cp eroi e r n mp iln ol eu ad crti pex op ior fve c sae jr e alc ib nter ya ln ro mt g oo kfn niw na inggo g e r tl od w ge drn eedt cee w eao k n r e tk hf io nr lc uee nr l e sen srg e ta h gs eue dbm ij see ccn lott ure marked wit h b p c p c l osurea ddse cx aeat te esler cn ora fi fpl tathois eo ss tuno rr rea gcn aec nne izt aretipoon rt pror aeau ycr f et picr uee rs p n ocs eee n vlioroonkimnge natt gree n house gas prevention su dn g u gn c ppapge r op uo nr dt rg bdisclosure references gri standards appendix gilead p appendix gilead p creporting period covers jan dec gri management approach c l u des worldwidi wi rn de eo f eso srni tkrt atem eis tfreya sfi mto niorg e nw na tohn snid c f eg inlp ei fl ol ceo rtay midne g ame ia tia nnn k tad ei hno oethdld eoerpr se rationala chp n npoe p pp pn e ett ro n dla ioal ox x n fs f qda cth hub e eao rr r u pe mt fg aod nio l u aye ytt ea ga ei agl ed ai ret ri ie ino ens f n r rc tei eor v se vr ipc tie aeto wl kwyr e hi htn ae lf da b ec e ri el et ni ne c gs r r ge ep c mo tr e et de n p worldwide bi wn ex oof ppo urlokr nam er dntr aa iasn rt g yi io cn ny ocn lfe te hm e p mlo ay tee ias la tn od p io c ah ne dr aanpnpueanld ix gilead p p saupppprolya cchha tion stakeholder engagement panradc mticaetse ria elintyv ironment responsible delivery systems p l l isclosures refc rt eteh suo rpe epn con pt om cral mteyc gpcn p oha roa ng iii ee nn nmt tf seo nr sq tu ape nps drt aoio ra dnc ssh ar nae dng da h r ad vi en g rth epe rtink cp ga eso r np prar gepac ratbe gii gocn iz lde ed eu mi aokx f ea jc n ce av tosn n ai mrv c n e mr p n mrn aa se tg edn e trte om dlert tn ee ypt cs u p bot lani cks eiab hfl feoa lid dr usee nrl li ev se sr th ey ds se cm los u marked w h b r cp p worldwide kcehya ntogpeisc sin rnedp ocortnincge rns raised worldwide b c rd eis pc ol ro ts inu gre p r ee rf ie de n cc oe vs e g rsr ji n n toa r dds e c worldwide ie frt isi nn eg psn ntu oi cep ri tc isp aia n l liyn n gs c c palc hu eth ad era imen dg e ne ts tt ho e h coe n sr og la idn aiz tea dti po ru ar c p tiu cerp e e n vb iro ou nt eh nis r ep prt nsible delivery systems pp p dincludes worldwidc ges itev sil rg isini lm ustuief tpasis ac p nofai loo dyfn nr art c ew roc hdphfh oait c nhrnth eig n gemgsi al ietnnoa aa dtgc hmceeoma oriendrgtnaaatni nncaeeipzd paw ortoiipotahenc r tahaht nieod n alop cruaornc pttirucorelp sao nsd eeon arv bpiraooiudnt uttehilniistti ser pdeiosrpretoc tnlysi binle delivery systems pp purpose report gri economic performance pd bdr oe ae utf ci enn di oun aftg rmo ier ne osap r rr ept crc eo n nn c tt pe reln e pt oa r rn tad p po rp oic ch mp ap ye n ix approach csr p g dprr irei ec c cao tu n etticoe onn nat rin dpicer xivn acliupele g oern aepraptreoda ch ga oprp ui c n pod uni rtxe pn ot u einr lae opx op kr io na gc h tt c r p pp distributed external initiatives aopupre pnudripxo csesr mboaunta tgheims ernetp osrtta keholder engagement p eexxtteerrnnaall ainsistiuartaivnecse p oraucr tpicuersp os een vaibroonumt tehnits grerepeonrth ouse gas prevention pp worldwide lriespt oorft minagt ceyricalle opics aanndn umaal teriality p defined benefit plan obligations working gilead compensation financial p retirement plans benefits memberships associations science innovation partnerships p memberships associations science innovation partnerships p contact point questions regarding korab zuka vice president public affairs report tcshre tgoitlaela sdqcuoamre footage corporate facilities reported gri anticorruption srteastteamteemnet nfrtosm fs iennfoiorrm daeticoisni onmaker oonu rp pur poof stehe c eo l eyettaerr review corrected p statement senior decisionmaker purpose ceo letter p p year review worldwide claims reporting accordance operations assessed risks related purpose report p gri standards aall disclosures refceorernrucpe tgiorni standards reporting period jan dec unless disclosure marked b c bdisclosure references gri standards vc gah rla iu n ceg ose n ps te ri ninn c r iei npp dloe ers xt nstga ndards norms gp rp e cn od ni tx e u inr dg eo xv erning principles pp c ar nae clp duo idr st cei ln g sw oree rsr ldi ro wed fie dc rcv eo ea n v sl cmeu ietre em gss j ru f inp n irr c wn c th sip c tnl ahe n gdn idso rldt e td sar n da aed nic mn da r hd iag ns v eaa bian reeu dn pt ooo rpr tm ienrgs tpieornioadla cop pofp npje aternn nod ld aix xn tou h rtr oe pg daco eiodv cde uer tn wli teg ie ssp r duai inn nrlc eedi cs p tsbll ye tyh ei n isclosure marked b c p p worldwide purpose report p b disclosure referencaens tgircio rrup stitoannd paordlsicies procedures reporting period c reporting period covers jan dec includes worldwide sites gilead maintained operational control andor paid utilities directly e eex nxet vec irru ont naiv ml ea esl nes tvu aer la l nr nec dsep cs iaib l tl oit py co sr economic ap pra pc eti nc de x e un rv air po pn rm oae cn ht tg cee sn rh ouse gas prevention p p c ae ecx noe tvn ic oif rui nortm sni v mtee ad e kl ne ein tv nace li ld nen dstp oon cfs ic aibo l ir tlr oitu pyp ctoi sor ne caonndo mic appendix approach csr p disclosures referednacete g orif mos ts traencdeanrdt sr eanpdo hrta reporting period mof ajyan dec unless disclosure marked b c b disclosure references gri standards gri energy c reporting period covers jan dec appendix csr management stakeholder engagement p appendix csr management stakeholder engagement p c lu es worldwide sl riit ese pts oofo rf r ts iw nta ghki c ceh yh cgo li elled aedr mgaroinutapinse operational control aaannnddno umr pala tiedr uiatilliittiye directly eli ns et ro gf cta ok ne sh uo mld pe tir g nr wou itp hs apnrda cmticaetesr ia leitnyv ironment worldwide energy c p organization consumption b dl il cd li os sc ulo resu rr ee fs e rr ee nfc cero epe snn gc ra te rc tg p ro ii n f tr nq dtua aen rsd dta si ordnss arnedg ahradvien ga rtehpeo rtink cg p rr earb gio iz ld eu aok dfa j c av oni mc e presid teo ndte pcu blic affai rusn less disclosure marked b c energy consumption outside gilead currently track energy consumption creporting period covers jan dec organization outside organization may dincludes worldwide sites gilead maintained operational control andor paid utilities directly future claims reporting accordance b c rd el cl p l cd uol dros esc inu slo gr wes pu er e r lf dis e wrr dee nf dcg ge c er er r ssi ien tg rs cc est oe sr j n gn fi n er ra n wr h ns c h ea x gs n dt ia la en r ad da e r c md ia nn ad nh ea dv e p er ap ior nti lo gg c rup ie n r cp ti ro ou od nr lp tao eo nf ns dje ta nra pb eao x iu u ih l er se e dpc io r ert c tl n u n less disclosure marked b p pc b c rd n el cl p lcd uoli drocs es c inu slo gr wes pu er e r lf dis e wrr dee nf dcee c enr e ses en r tg rc g ese sry j g fi ai nr rt e w n h c h gs n dt ia la en r ad da e r c md ia nn ad nh ea dv e p er ap ior nti lg p c c rp oae n ncr tsit ruoi ocd le aos p n f dij ae onnn r v pi ar dn um ie l int tot e sw e doc ir rl ed cw tl yi ie n e n ue nr gleys disclosure marked wit h b c p p worldwided c reduction energy consumption practices environment energy efficiency external assurance practices environment greenhouse gas prevention p gilead currently track reductions energy reductions energy requirements requirements associated manufacturing products services products may future gri water b dl il cd li os sc ulo resu rr ee fs e rr ee nfe cr ee sn gce r g r ta ndta rd da rds reporting period jan dec unless disclosure marked b c b c water consumption practices environment better water management p worldwided creporting period covers jan dec dincludes worldwide sites gilead maintained operational control andor paid utilities directly aall disclosures reference gri standards reporting period jan dec unless disclosure marked b c bdisclosure references gri standards creporting period covers jan dec dincludes worldwide sites gilead maintained operational control andor paid utilities directly year review un un reporting disclosurea description reference sdg gc boundary gri management approach explanation material topic boundary management approach appendix csr management stakeholder components engagement materiality p worldwide appendix appendix evaluation management approach gri economic performance direct econ omic value geenearart eidn review year review purpose looking p distributed worldwide defined benefit plan obligations working gilead compensation financial p disclosurea dre etir se cm rie pn tt op nla ns rbe en feef ri ets n ce un un reporting disclosurea description reference un un reporting sdg gc boundary sdg gc boundary ggrrii maanntiacgoermruepntti oanp proach gri emissions explanation material topic operations assessed risks related c direct scope ghg emissions boundary corruption management approach appendix csr management stakeholder ictso mcommupnoicnaetniotsn training aen pg pa eg ne dm ixe n tt h en cd da et wer eia slit ty nd p p ww oo rr dd ww ii dd ee c indirect scope ghg emissions p anticorruption policies procedures evaluation management approach c indirect scope ghg emissions practices environment ghg reduction worldwided confirmed incidents corruption initiatives gri economica pcetirofnosrm taaknecne c ghg emissions intensity gri enedrgirye ct economic value generated purpose looking p distributed c energy consumption within practices environment worldwide energy p worldwide c reduction ghg emissions p odregfainneizda btieonne fit plan obligations cwoonrksuinmgp attio gni lead compensation financial p retirement plans benefits gilead currently track energy consumption outside gilead currently track energy consumption emissions ozonedepleting substances ods ozonedepleting substances organization outside organization may may future gri anticorruption future gri effluent c eo conp ree rr urga pyt ti ioi onn ntse nassistye ssed risks related p cr oa nc st uic mes p io e nn vironment worldwide energy p worldwided c waste type disposal method p practices environment increased recycling c creodmumctuionnic oatfi oenn earngdy tcroaninsiunmg patbioonu practices environment energy efficiency efforts p worldwided anticorruption policies procedures appendix code stand p worldwide c transport hazardous waste c ar pcreo otdn idoufi uncr cm sti ste aks nei ni dnnc sied ene vnr cgs ey r fe cqourirruepmtieonnt sa nodf g rei qle ua id mo ee ns sn sc ou crr iae tn et dly wtr ia thck r ae nd uu fc cio tun rs nin g e itn se rgy gri supplier environmental assessment products may future new suppliers screened using practices environment risk management gri energy environmental criteria performance p gri water worldwide energy consumption within practices environment worldwide energy c organization consumption p negative environmental impacts supply chain practices environment auditing procedures b c water consumption practices environment better water management p worldwided actions taken gilead currently track energy consumption p energy consumption outside outside organization may organization gri employment future c energy intensity practices environment worldwide energy new employee hires employee turnover working gilead people numbers p consumption p worldwided p b c rd el il p cd oli rocs c inulo gres pu r er ee rf e rr dee nf cre c oer e sd en ug rc sce r j ig ao nnr f e n ea rs ng dt ta oan rc dd doa en r cd us n p h n v e reporting p rp ae cri icd e f j en n v ir n e nto enec e r g e f fi c ie u nn cl ye ss disclosure marked w th b c b noe tn pe rfi ots v ip dr eo dv td oe td e mto p f ou rl al rt yim oe r pe rp tl imye ee es th pa lot ya ere e working gilead reward p worldwide dincludes worldwide sites gilead maintained operational control andor paid utilities directly recognize retain employees reductions energy requirements gilead currently track reductions energy parental leave p requirements associated manufacturing products services products may future disclosures reference gri standards reporting period jan dec unless disclosure marked b c disclosures reference gri standards reporting period jan dec unless disclosure marked b c b disclosure references gri standards b disclosure references gri standards cg rreip orting w peartieodr covers jan dec c reporting period covers jan dec includes worldwide sites gilead maintained operational control andor paid utilities directly includes worldwide sites gilead maintained operational control andor paid utilities directly b c water consumption practices environment better water management p worldwided aall disclosures reference gri standards reporting period jan dec unless disclosure marked b c b c rd eis pc ol ro ts inu gre p r ee rf ie de n cc oe vs e g rsr ji n n toa r dds e c b dl il cd li os sc ulo resu rr ee fs e rr ee nfe cr ee sn gce r g r ta ndta rd da rds reporting period jan dec unless disclosure marked b c dincludes worldwide sites gilead maintained operational control andor paid utilities directly creporting period covers jan dec dincludes worldwide sites gilead maintained operational control andor paid utilities directly year review un un reporting disclosurea description reference sdg gc boundary gri occupational health safety workers representation formal joint managementworker health safety committees working gilead building culture p worldwide workplace safety types injury rates injury b occupational diseases lost days absenteeism number workrelated fatalities gri training education working gilead professional personal average hours training per year per employee p development worldwide percentage employees receiving regular working gilead compensation p performance career development reviews financial benefits gri diversity equal opportunity working gilead people diversity governance bodies employees p us numbers ratio basic salary remuneration women working gilead compensation p us men financial benefits gri local communities appendix appendix operations local community engagement community impact giving back p worldwide impact assessments development programs communities gri supplies social assessment year review year review new suppliers screened using social p criteria practices environment risk management worldwide performance disclosurea description reference su dn g u gn c r op uo nr dt rg disclosurea dn ace etg isoa cnt ri sv pe ta ts kio oec nni l impacts supply chain reference su dn g u gn c ppage r op uo nr dt rg year review gri occupational health safety ggrrii coucsctuopmaetiro hneaal hlthe aalnthd asnadfe stya fety workers representation formal joint workers representation formal joint managementworker health safety committees working gilead building culture p worldwide c losurea da prsa eosn dsea ucsgs crme itp ae tnine odtn nto ef w rt vho ie cr k ehe e cra hl tt eeh ga oltnh rid ea ssn adf estayf eimtyp caocmtsm oift tees p trwrr ea oa nfrc ekst ii prnc eae gnrs e c n te c ge le v air n bm ue iln dt n ga afe cty u l te ut rh eic os f nd su dn g u gn c pa pp g e r bw oo op ur rl lod ndw wr dti iaid dn eg workplace safety workplace safety types injury rates injury types injury rates injury b occupational diseases lost days gri b marketinogc caunpda ltiaobnealli ndgis eases lost days absenteeism number workrelated fatalities absenteeism number workrelated fatalities requirements product service information gri training education gri traininga anndd l aebdeulcinagti aall disclosures rienfceirdeencnets g orf inn oonnccoo smmtpapnlliidaaannrccdees acnodn chearvnei nag r epproordtiuncgt paenrdio jan dec unless disclosure marked b c average hours training per year per employee dw eo vr eki ln og p mat e g ntil ead professional personal p b c r eis p c ol ro ts inu gre p r ee rf ie de n ecvc roeve vrs iaec g grese r j hi u r ft ta rn tiona r idnd gs e c p er ear per employee dp tw rr eaoa vnrc ek stii lpnc oaeg prs mea nt e cg ne ytin l evairdon mpreonftes ssaiofentayl aenthdi cpse arsnodn al pp worldwide dincludes worldwide sites gilead maintained operational control andor paid utilities directly worldwide worldwide incidents nnoonnccoommpplliiaannccee concerning marketing p pe er rc foe rn mta ag ne c eo f e nm p calo ry ee ee r ere vc ee loiv pin mg e r ne tg ru el va ier ws fw ino ark ni cn ig la bt eg nil ee fa itd compensation p p pcoe emr rc fome rn mutna aigc nea c eoio f ne nsm p calo ry ee ee r ere vc ee loiv pin mg e r ne tg ru el va ier ws fw ino ark ni cn ig la bt eg nil ee fa itd compensation p gri customer privacy gri diversity equal opportunity gri diversity equal opportunity diversity governance bodies employees nw uo mrk bin eg rs gilead people p us ds cuu iv sb e ts ort eyt r oa pft g id vo vc ceo yrm n ap nl n da c ln e ot sbs oc edo si n e oc fe car un n si dn og e mb er pe rl oa dyc aeh te ae ss np tw rr uaoa mnrck st bii pnc eaeg rrss ea nt cge yin levairdon moeunr tp esoapfelety b ye tthhiec pp wuosrld ownidlye r ana dti ef n b asic salary remuneration women fw ino ark ni cn ig la bt eg nil ee fa itd compensation p us r ana dti ef n b asic salary remuneration women fw ino ark ni cn ig la bt eg nil ee fa itd compensation p us gri local communities gri local communities imp pe ar ca tt ao sn ss e w ssit mh elo nc tsa l c dm dm evu en li oty p men eg na g pe rom ge rn c co om mm mu un ni ty ie sm pact giving back p worldwide imp pe ar ca tt ao sn ss e w ssit mh elo nc tsa l c dm dm evu en li oty p men eg na g pe rom ge rn c co om mm mu un ni ty ie sm pact giving back p worldwide gri supplies social assessment gri supplies social assessment new suppliers screened using social new suppliers screened using social p p criteria criteria practices environment risk management practices environment risk management worldwide worldwide performance performance negative social impacts supply chain n ace tg ioa nti sv e ta ko ec ni al impacts supply chain p actions taken p gri customer health safety gri customer health safety disclosures reference gri standards reporting period jan dec unless disclosure marked b c disclosures reference gri standards reporting period jan dec unless disclosure marked b c b disclosure references gri standards b disclosure references gri standards c reporting period covers jan dec c reporting period coavsesrse jsasnm e nt ttoh dee hce alt h safety impacts practices environment safety ethics includes worldwidaes ssietesss mfore wnht iochf tghilee ahde maaltihnt aainnded oapfeertayt iiomnapla ccotnst roofl andor ppairda ucttiilcitieess di reenctvlyir ion nment safety ethics p worldwide includes worldwidep sriotedsu focrt wanhidch geirlveiacde caaintetaginoerdie osp erational control andor paitdr auntilsitpieasr deinreccyt ly p worldwide product service categories transparency aall disclosures reference gri standards reporting period jan dec unless disclosure marked b c b dl il cd li os sc ulo resu rr ee fs e rr ee nfe cr ee sn gce r g r ta ndta rd da rds reporting period jan de c unless disclosure marked b c bdisclosure references gri standards creporting period covers jan dec creporting period covers jan dec dincludes worldwide sites gilead maintained operational control andor paid utilities directly dincludes worldwide sites gilead maintained operational control andor paid utilities directly aall disclosures reference gri standards reporting period jan dec unless disclosure marked b c bdisclosure references gri standards creporting period covers jan dec dincludes worldwide sites gilead maintained operational control andor paid utilities directly